CombiMatrix and Manhattan Labs Enter Strategic Partnership to Service NYC Metropolitan Area

CombiMatrix and Manhattan Labs Enter Strategic Partnership to Service NYC
Metropolitan Area

Geographic Base Continues to Broaden on Heels of NY Licensing

IRVINE, Calif., and NEW YORK, Aug. 13, 2013 (GLOBE NEWSWIRE) -- CombiMatrix
Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in
DNA-based testing services for developmental disorders and cancer diagnostics,
and Manhattan Labs jointly announced today that they have entered into a
strategic partnership under which Manhattan Labs will market and distribute
CombiMatrix microarray tests for the miscarriage management testing market in
the New York City metropolitan area. The partnership was enabled by the
announcement in late June that CombiMatrix miscarriage management tests had
received conditional approval from the New York State Department of Health for
testing on patient samples within the state.

Manhattan Labs is a high-end, independent clinical laboratory that serves the
New York City metropolitan area. Women's health, particularly obstetrics and
reproductive issues, is one of Manhattan Lab's specialties, noted Chief
Executive Officer Ken Cerney.

"Our goal is to be the premier, full-service independent clinical laboratory
in the New York City area," Cerney said. "Our labs offer the highest quality
testing for all patients and now we have added a new focus on miscarriage
management. We believe adding the operational and analytical support of
CombiMatrix will be beneficial to our physician customers and their patients,
and will expand the breadth of services we provide. We also believe in the
growing importance and clinical advantages microarray testing provides for
appropriate patients and look forward to working in partnership with
CombiMatrix."

Miscarriage management testing, a subset of the overall prenatal testing
market, allows OB/GYN physicians and clinicians to better determine if there
is a genetic cause for a miscarriage or other related events. As in other
areas of prenatal genetic analysis, microarray testing is believed by many to
be the coming standard of care as it identifies a greater number of possible
genetic abnormalities more accurately than traditional methods.

CombiMatrix President and Chief Executive Officer Mark McDonough noted that
this partnership with Manhattan Labs enables CombiMatrix to broaden the
geographic reach of its leading growth product into the important New York
metropolitan area. At the same time, the partnership demonstrates that
microarray testing is gaining acceptance as a preeminent diagnostic in the
field of high quality women's health.

"Clinical data is showing that, in terms of women's health, microarray testing
is quickly becoming the standard of care for miscarriage management testing,"
McDonough said. "For CombiMatrix, our goal is to partner with the very best
and most respected independent labs around the country and we are excited to
be teaming up with such an important company as Manhattan Labs. Adding its
marketing and distribution support to our own internal sales efforts promises
to be very beneficial to our growth and prosperity."

About Manhattan Labs

Manhattan Physicians Laboratories, LLC ("Manhattan Labs") was founded in 2008
with the goal of creating the premier service-oriented, high-quality
independent clinical laboratory in New York City and the surrounding tri-state
area. Combining the latest in clinical laboratory technology, personalized
service, exceptional turnaround time and easy-to-access results, Manhattan
Labs is continuing to elevate the standards and set a new benchmark of service
in the laboratory industry. www.ManhattanLabs.com

About CombiMatrix Corporation

CombiMatrix Corporation provides valuable molecular diagnostic solutions and
comprehensive clinical support for the highest quality of care. CombiMatrix
specializes in miscarriage analysis, prenatal and pediatric healthcare,
offering DNA-based testing for the detection of genetic abnormalities beyond
what can be identified through traditional methodologies.CombiMatrix performs
genetic testing utilizing a variety of advanced cytogenomic techniques,
including microarray, standardized and customized FISH, and high resolution
karyotyping. Additional information about CombiMatrix is available at
www.combimatrix.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995.These statements are based upon our current expectations, speak only
as of the date hereof and are subject to change.All statements, other than
statements of historical fact included in this press release, are
forward-looking statements.Forward-looking statements can often be identified
by words such as "anticipates," "expects," "intends," "plans," "goal,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "could," "potential," "continue," "ongoing," "objective," similar
expressions, and variations or negatives of these words and include, but are
not limited to, statements regarding the advantages and efficacy of CMA over
standard karyotyping.These forward-looking statements are not guarantees of
future results and are subject to risks, uncertainties and assumptions that
could cause our actual results to differ materially and adversely from those
expressed in any forward-looking statement.The risks and uncertainties
referred to above include, but are not limited to:market acceptance of CMA as
a preferred method over karyotyping; the rate of transition to CMA from
karyotyping; our ability to successfully expand the base of our customers and
strategic partners, add to the menu of our diagnostic tests in both of our
primary markets, develop and introduce new tests and related reports, optimize
the reimbursements received for our testing services, and increase operating
margins by improving overall productivity and expanding sales volumes; our
ability to successfully accelerate sales, allow access to samples earlier in
the testing continuum, steadily increase the size of our customer rosters in
both developmental medicine and oncology; our ability to attract and retain a
qualified sales force; rapid technological change in our markets; changes in
demand for our future products; legislative, regulatory and competitive
developments; general economic conditions; and various other factors.Further
information on potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q,
and in other filings with the Securities and Exchange Commission.We undertake
no obligation to revise or update publicly any forward-looking statements for
any reason, except as required by law.

CONTACT: CombiMatrix Contact:
         Mark McDonough
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624
        
         Media Contact:
         Len Hall
         VP, Media Relations
         Allen & Caron
         Tel (949) 474-4300
         len@allencaron.com
        
         Investor Relations Contact:
         John Baldissera
         BPC Financial Marketing
         Tel (800) 368-1217
        
         For Manhattan Labs inquiries:
         Laura Johnson
         Manhattan Labs
         212-874-0500
         ljohnson@manhattanlabs.com

CombiMatrix Corporation